Lansoprazolo Hexal

Lansoprazole, the active ingredient in Lansoprazolo Hexal, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and related disorders in adult patients.

GNH USA supplies Lansoprazolo Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole acts on the gastric acid‑secretion pathway and is indicated for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing stomach acidity. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through acid suppression. - Helicobacter pylori eradication regimens: enhances antibiotic effectiveness when combined with clarithromycin and amoxicillin. - Erosive esophagitis: heals inflamed esophageal tissue by maintaining a higher gastric pH.

Lansoprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Diarrhea: loose, frequent stools. - Nausea: sensation of unease and urge to vomit. - Abdominal pain: discomfort or cramps in the stomach area. - Flatulence: excess gas causing bloating. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe allergic reactions: rash, itching, swelling, or difficulty breathing. - Clostridium difficile infection: severe colitis presenting with watery diarrhea. - Liver enzyme elevation: increased ALT or AST indicating hepatic stress. - Stevens‑Johnson syndrome: painful skin blistering and mucosal involvement. - Acute interstitial nephritis: kidney inflammation causing reduced urine output. - Pancreatitis: inflammation of the pancreas with abdominal pain and vomiting.

Before prescribing Lansoprazole, clinicians should consider several safety aspects. - Renal function assessment: adjust use in patients with severe kidney impairment. - Hepatic impairment: monitor liver function tests during therapy. - Known hypersensitivity: avoid in individuals with documented allergy to lansoprazole or other PPIs. - Long‑term use monitoring: be aware of potential increased risk of bone fractures and vitamin B12 deficiency. - Drug interaction vigilance: review concomitant medications that may affect metabolism. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: may increase lansoprazole levels, raising risk of toxicity. - Ketoconazole: reduced absorption of ketoconazole leading to therapeutic failure. - Atazanavir: decreased atazanavir exposure, compromising antiviral efficacy.

Moderate Interactions (Monitor Closely): - Phenytoin: may lower lansoprazole concentrations, requiring efficacy monitoring. - Carbamazepine: can reduce lansoprazole exposure, potentially diminishing acid suppression.